EA200601404A1 - Полиморфные формы агониста gaba - Google Patents

Полиморфные формы агониста gaba

Info

Publication number
EA200601404A1
EA200601404A1 EA200601404A EA200601404A EA200601404A1 EA 200601404 A1 EA200601404 A1 EA 200601404A1 EA 200601404 A EA200601404 A EA 200601404A EA 200601404 A EA200601404 A EA 200601404A EA 200601404 A1 EA200601404 A1 EA 200601404A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polymorfniie
agonista
gaba
forms
new crystalline
Prior art date
Application number
EA200601404A
Other languages
English (en)
Other versions
EA009413B1 (ru
Inventor
Винсент Бретт Купер
Original Assignee
Мерк Шарп Энд Домэ Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601404(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Шарп Энд Домэ Лимитед filed Critical Мерк Шарп Энд Домэ Лимитед
Publication of EA200601404A1 publication Critical patent/EA200601404A1/ru
Publication of EA009413B1 publication Critical patent/EA009413B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

В заявке описаны два новых кристаллических моногидрата и два новых кристаллических ангидрата габоксадола, а также способы их приготовления.
EA200601404A 2004-01-30 2005-01-28 Полиморфные формы габоксадола, агониста gaba EA009413B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist
PCT/GB2005/000288 WO2005073237A2 (en) 2004-01-30 2005-01-28 Polymorphic forms of a gabaa agonist

Publications (2)

Publication Number Publication Date
EA200601404A1 true EA200601404A1 (ru) 2006-12-29
EA009413B1 EA009413B1 (ru) 2007-12-28

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601404A EA009413B1 (ru) 2004-01-30 2005-01-28 Полиморфные формы габоксадола, агониста gaba

Country Status (35)

Country Link
US (2) US7262300B2 (ru)
EP (2) EP2042505A1 (ru)
JP (1) JP4917440B2 (ru)
KR (1) KR101210361B1 (ru)
CN (1) CN1914212B (ru)
AR (1) AR047511A1 (ru)
AT (1) ATE414088T1 (ru)
AU (1) AU2005209473B2 (ru)
BR (1) BRPI0506858A (ru)
CA (1) CA2554536C (ru)
CO (1) CO5700743A2 (ru)
CY (1) CY1108647T1 (ru)
DE (1) DE602005010975D1 (ru)
DK (1) DK1713813T3 (ru)
DO (1) DOP2005000013A (ru)
EA (1) EA009413B1 (ru)
EC (1) ECSP066735A (ru)
ES (1) ES2314613T3 (ru)
GB (2) GB0402118D0 (ru)
HK (1) HK1096547A1 (ru)
HR (1) HRP20080614T3 (ru)
IL (1) IL176863A0 (ru)
MA (1) MA28364A1 (ru)
MX (1) MXPA06008595A (ru)
MY (1) MY139525A (ru)
NO (1) NO20063843L (ru)
NZ (1) NZ548191A (ru)
PE (1) PE20050769A1 (ru)
PL (1) PL1713813T3 (ru)
PT (1) PT1713813E (ru)
SI (1) SI1713813T1 (ru)
TW (1) TWI345972B (ru)
UA (1) UA87487C2 (ru)
WO (1) WO2005073237A2 (ru)
ZA (1) ZA200605307B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (en) * 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPHIC FORMS OF A GABAA AGONIST
DK1928405T3 (da) 2005-09-28 2014-12-15 Auris Medical Ag Farmaceutiske sammensætninger til behandling af indre øreforstyrrelser
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
ES2862673T3 (es) 2011-12-12 2021-10-07 Zilentin AG Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo
PE20190338A1 (es) * 2015-07-17 2019-03-07 Ovid Therapeutics Inc Metodos de tratamiento de trastornos del desarrollo con gaboxadol
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
AU2018309049A1 (en) 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4315934A (en) 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (ru) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводная кристаллическая форма гидрохлорида r(-)-n-(4,4-ди(3-метилтиен-2-ил)бут-3-енил) нипекотиновой кислоты
AU7405000A (en) 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
EP1399138B1 (de) 2001-05-18 2006-02-08 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
AU2002338855B2 (en) 2001-05-21 2007-08-16 H. Lundbeck A/S Granular preparations of gaboxadol
CN100491366C (zh) * 2002-09-03 2009-05-27 华晶基因技术有限公司 汉黄芩素用作治疗焦虑症的药物的用途
DE602004025808D1 (de) * 2003-06-25 2010-04-15 Lundbeck & Co As H Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
WO2005023256A1 (en) 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EA200700102A1 (ru) 2004-06-29 2007-06-29 Х.Лундбекк А/С Лечение невропатической боли, фибромиалгии или ревматоидного артрита
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPHIC FORMS OF A GABAA AGONIST
WO2006102093A1 (en) 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol

Also Published As

Publication number Publication date
CA2554536A1 (en) 2005-08-11
ECSP066735A (es) 2006-10-31
AR047511A1 (es) 2006-01-25
EP2042505A1 (en) 2009-04-01
KR20070007070A (ko) 2007-01-12
TWI345972B (en) 2011-08-01
JP4917440B2 (ja) 2012-04-18
US20050171142A1 (en) 2005-08-04
PE20050769A1 (es) 2005-10-04
EP1713813A2 (en) 2006-10-25
DOP2005000013A (es) 2005-08-15
HK1096547A1 (en) 2007-06-01
US7262300B2 (en) 2007-08-28
MA28364A1 (fr) 2006-12-01
CN1914212B (zh) 2010-10-06
NZ548191A (en) 2010-04-30
MXPA06008595A (es) 2006-08-28
DE602005010975D1 (de) 2008-12-24
EA009413B1 (ru) 2007-12-28
GB2410434A (en) 2005-08-03
CY1108647T1 (el) 2014-04-09
CA2554536C (en) 2012-09-18
EP1713813B1 (en) 2008-11-12
KR101210361B1 (ko) 2012-12-10
MY139525A (en) 2009-10-30
AU2005209473B2 (en) 2010-03-04
GB0402118D0 (en) 2004-03-03
CN1914212A (zh) 2007-02-14
AU2005209473A1 (en) 2005-08-11
CO5700743A2 (es) 2006-11-30
ATE414088T1 (de) 2008-11-15
DK1713813T3 (da) 2009-02-16
US8236958B2 (en) 2012-08-07
SI1713813T1 (sl) 2009-02-28
PT1713813E (pt) 2008-12-26
WO2005073237A3 (en) 2005-10-20
GB0501847D0 (en) 2005-03-09
TW200534856A (en) 2005-11-01
US20070259912A1 (en) 2007-11-08
HRP20080614T3 (en) 2009-01-31
IL176863A0 (en) 2006-10-31
NO20063843L (no) 2006-08-29
ES2314613T3 (es) 2009-03-16
BRPI0506858A (pt) 2007-05-29
PL1713813T3 (pl) 2009-04-30
UA87487C2 (ru) 2009-07-27
WO2005073237A2 (en) 2005-08-11
ZA200605307B (en) 2007-11-28
JP2007519697A (ja) 2007-07-19

Similar Documents

Publication Publication Date Title
EA200601404A1 (ru) Полиморфные формы агониста gaba
EA200602099A1 (ru) Получение прегабалина и родственных соединений
EA200801560A1 (ru) Бифенилкарбоксамиды
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA200801663A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1'-(1-МЕТИЛЭТИЛ)-4'-[(2-ФТОР-4-МЕТОКСИФЕНИЛ)МЕТИЛ]-5'-МЕТИЛ-1H-ПИРАЗОЛ-3'-O-β-D-ГЛЮКОПИРАНОЗИДА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
DK1957656T3 (da) Fermentativ fremstilling af lysin
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
EA200702347A1 (ru) Способ получения глюкопиранозилзамещённых производных бензилбензола и промежуточных продуктов для их получения
HK1182381A1 (zh) 吲哚胺 -二氧酶的調節物和使用其的方法
EA201070853A1 (ru) Кристаллический (r)-2-(4-циклопропансульфонилфенил)-n-пиразин-2-ил-3-(тетрагидропиран-4-ил)пропионамид
NO20075068L (no) Lipocalinprotein
EA201000496A1 (ru) Замещенное соединение миноциклина, способ получения замещенных соединений миноциклина (варианты)
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
DK1893587T3 (da) Fremgangsmåde til fremstilling af dihydroquinazoliner
EA200700199A1 (ru) Способ получения дигидроптеридинонов
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
EA200800595A1 (ru) Композиции политиоуретана и способы получения и применения композиций политиоуретана
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
EA200601390A1 (ru) Композиции модафинила
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
EA200701592A1 (ru) Композиты и способы их получения и использования
EA200801414A1 (ru) Кальцилитические соединения
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU